The FDA has approved isatuximab-irfc (Sarclisa®, Sanofi) in combination with carfilzomib and dexamethasone (Kd), for adult patients with relapsed or refractory multiple myeloma who have previously received one to three lines of therapy. "Treatment of relapsed/refractory multiple myeloma (RRMM) has greatly improved, yet relapse is inevitable and additional effective treatments are needed," wrote Philippe Moreau, MD, Head of the Hematology Department at the University Hospital of Nantes in France,...